Stride Arcolab has received US FDA approval for parnidronate disodium injection, 3mg/ml and 9mg/ml for single use vials. The product is licensed to Akorn-Strides, LLC, which is a joint venture that was formed in 2004 by Akorn Inc and Strides.
Ravi Seth, CEO - International Operations, said, "It is indeed gratifying that with 12 ANDA approvals, the Strides Akorn JV has a good sized offering of generic injectable products for the US markets. The JV which posted a healthy performance during third quarter of 2008, expects to have all these products launched in the market by Q1 of 2009."